ADI1 and hepatocellular carcinoma: In a paper published in 2019, Chu et al. showed that in HCC, the increase of AdoMet levels, promoted by upregulation of acireductone dioxygenase 1, a key enzyme involved in the MTA cycle, altered the promoter methylation status of different cancer-related genes and of genes encoding lncRNAs and miRNAs, leading to downregulation of their expression and to HCC growth suppression [83].